Download PDF
Thromb Haemost 1997; 78(01): 261-265
DOI: 10.1055/s-0038-1657536
New recombinant products in the treatment of hemophilias
Schattauer GmbH Stuttgart

Recombinant Factor IX

Authors

  • Gilbert C White II

    Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

  • Aime Beebe

    Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA

  • Brenda Nielsen

    Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis, Comprehensive Hemophilia Diagnosis and Treatment Center, University of North Carolina, Chapel Hill, NC, USA
Further Information

Publication History

Publication Date:
12 July 2018 (online)

 PDF Download  Permissions and Reprints
Preview Container
 

  • References

  • 1 Nishimura H, Kawahata II S, Kisiel W, Hase S, Ikenaka T, Takao T, Shimonishi Y, Iwanaga S. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem 1989; 264: 20320-20325
    PubMedSearch in Google Scholar
  • 2 Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B. Recognition site directing vitamin K-dependent γ-carboxylation residues in the propeptide of factor IX. Cell 1987; 48: 185-191
    CrossrefPubMedSearch in Google Scholar
  • 3 Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. Pace/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268: 8458-8465
    PubMedSearch in Google Scholar
  • 4 Femlund P, Stenflo J. β-Hydroxyaspartic acid in vitamin K-depedent proteins. J Biol Chem 1983; 258: 12509-12512
    PubMedSearch in Google Scholar
  • 5 Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819
    PubMedSearch in Google Scholar
  • 6 Gerritzen A, Schneweis KE, Brackman H-H, Oldenburg J, Hanfland P, Gerlich WH, Caspari G. Acute hepatitis A in haemophiliacs. Lancet 1992; 340: 1231-1232
    PubMedSearch in Google Scholar
  • 7 Mariani G, di PaolantonioT, Baklaya R, Morfmi M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. Transfusion 1993; 33: 814-818
    CrossrefPubMedSearch in Google Scholar
  • 8 Flores G, Juarez JC, Montoro JB. et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia 1995; 01: 115-117
    CrossrefPubMedSearch in Google Scholar
  • 9 Hepatitis A among persons with hemophilia who received clotting factor concentrate-United States. 09 1995; MMWR (Atlanta, Ga: Centers for Disease Control. US Department of Health and Human Services publication). 1996; 45: 29-32
    PubMedSearch in Google Scholar
  • 10 Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Brit J Haemat 1996; 93: 457-459
    CrossrefPubMedSearch in Google Scholar
  • 11 Ragni MV, Koch WC, Jordan JA. Parvovirus B19 infection in patients with hemophilia. Transfusion 1996; 36: 238-241
    CrossrefPubMedSearch in Google Scholar
  • 12 Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant ϒ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-9628
    PubMedSearch in Google Scholar
  • 13 Bond MD, Patel H, Huberty MC. et al: Structural and biological characterization of Gla-related isoforms of recombinant human factor IX shows that Gla36 and Gla40 are not essential forin vitrolotting activity. Thrombos Haemostas 1995; 73: 1167-1168
    Search in Google Scholar
  • 14 Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD. y-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997; 06: 185-196
    Search in Google Scholar
  • 15 Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Lappanen SD, Rup BJ, Keith Jr JC, Garzone PD, Schaub RG. Recombinant factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2803-2810
    Search in Google Scholar
  • 16 Kim HC, McMillan CW, White II GC, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575
    PubMedSearch in Google Scholar
  • 17 Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. Am J Hemat 1992; 40: 210-215
    CrossrefPubMedSearch in Google Scholar
  • 18 Bemtorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thrombos Haemostas 1993; 70: 768-773
    Search in Google Scholar
  • 19 Poon M-C, Aledort LM, Anderle K, Kunschak M, Morfmi M. Comparison of the recovery and half-life of a high purity factor IX concentrate with those of a factor IX complex concentrate. Transfusion 1995; 35: 319-323
    CrossrefPubMedSearch in Google Scholar